{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-068277","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.308175+00:00","generated_at":"2026-06-07T18:07:26.956252+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Olema reports positive Phase 1b/2 combo data for palazestrant; Phase 3 OPERA-01 enrolling","bullets":["Palazestrant + ribociclib (19 patients) well-tolerated; no dose-limiting toxicities, no drug-drug interaction.","Palazestrant + palbociclib (46 patients): clinical benefit rate 46% overall, 60% in ESR1 mutant, 71% in CDK4/6-naïve.","OPERA-01 Phase 3 monotherapy trial initiated; first patient dosed November 2023; sites activated.","Company anticipates potential Phase 3 combo trial start with ribociclib as early as end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-068277","json":"https://secwatch.observer/filing/0000950170-23-068277.json","markdown":"https://secwatch.observer/filing/0000950170-23-068277.md","text":"https://secwatch.observer/filing/0000950170-23-068277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017023068277/0000950170-23-068277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017023068277/olma-20231205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:07:26.956252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}